Utilization of intravenous lidocaine infusion for the treatment of refractory chronic pain
Author
Tully, J.Jung, J.W.
Patel, A.
Tukan, A.
Kandula, S.
Doan, A.
Imani, F.
Varrassi, G.
Cornett, E.M.
Kaye, A.D.
Viswanath, O.
Urits, I.
Affiliation
College of Medicine-Phoenix, University of ArizonaIssue Date
2020
Metadata
Show full item recordPublisher
Kowsar Medical InstituteCitation
Tully J, Jung J W, Patel A, Tukan A, Kandula S, et al. Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory Chronic Pain, Anesth Pain Med. 2020 ; 10(6):e112290.Journal
Anesthesiology and Pain MedicineRights
Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Context: Chronic pain accounts for one of the most common reasons patients seek medical care. The financial burden of chronic pain on health care is seen by direct financial cost and resource utilization. Many risk factors may contribute to chronic pain, but there is no definite risk. Managing chronic pain is a balance between maximally alleviating symptoms by utilizing a therapeutic regimen that is safe for long-term use. Currently, non-opioid analgesics, NSAIDs, and opioids are some of the medical treatment options, but these have numerous adverse effects and may not be the best option for long-term use. However, Lidocaine can achieve both central and peripheral analgesic effects with relatively few side effects, whichmaybe an idealcompoundfor managing chronic pain. Evidence Acquisition: This is a Narrative Review. Results: Infusion of lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide), an amino-amide compound, is emerging as a promising option to fill the therapeutic void for treatment of chronic pain. Numerous studies have outlined dosing protocols for lidocaine infusion for the management of perioperative pain, outlined below. While there are slight variations in these different protocols, they all center around a similar dosing regimen to administer a bolus to reach a rapid steady state, followed by infusion for up to 72 hours to maintain the therapeutic analgesic effects. Conclusions: Lidocaine may be a promising pharmacologic solution with a low side effect profile that provides central and peripheral analgesia. Even though the multifaceted mechanism is not entirely understood yet, lidocainemaybe a promising novel remedy in treating chronic pain in various conditions. © 2020, Author(s).Note
Open access journalISSN
2228-7523EISSN
2228-7531Version
Final published versionae974a485f413a2113503eed53cd6c53
10.5812/aapm.112290
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).

